Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance

  • US 10,253,100 B2
  • Filed: 09/28/2012
  • Issued: 04/09/2019
  • Est. Priority Date: 09/30/2011
  • Status: Active Grant
First Claim
Patent Images

1. An antibody comprising a modified IgG1 Fc region,wherein the amino acid at position EU438 of the modified Fc region is glutamic acid, arginine, serine, or lysine;

  • andwherein the amino acid at position EU440 of the modified Fc region is glutamic acid, aspartic acid, or glutamine.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×